Preclinical data for reversible BTK inhibitor RXC005 presented at the 17th International Workshop of Chronic Lymphocytic Leukemia
15 May 2017
The poster, entitled "RXC005, a Potent and Selective, Reversible BTK Inhibitor Targeting both Wild-type and Mutant C481S BTK with Potent Efficacy in ABC-DLBCL Xenograft Mouse Models", demonstrated that RXC005 successfully inhibits wild-type BTK and C481S mutant BTK, as well as B-Cell Receptor signalling in ABC-DLBCL cell lines and importantly primary CLL cells.